Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Liabilities (2019 - 2025)

Historic Total Liabilities for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $2.9 billion.

  • BridgeBio Pharma's Total Liabilities rose 5509.33% to $2.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 5509.33%. This contributed to the annual value of $2.4 billion for FY2024, which is 2583.68% up from last year.
  • BridgeBio Pharma's Total Liabilities amounted to $2.9 billion in Q3 2025, which was up 5509.33% from $2.9 billion recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Total Liabilities registered a high of $2.9 billion during Q3 2025, and its lowest value of $1.5 billion during Q1 2021.
  • Moreover, its 5-year median value for Total Liabilities was $1.9 billion (2024), whereas its average is $2.0 billion.
  • Per our database at Business Quant, BridgeBio Pharma's Total Liabilities surged by 21532.06% in 2021 and then crashed by 127.56% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Total Liabilities (Quarter) stood at $1.9 billion in 2021, then decreased by 0.55% to $1.9 billion in 2022, then rose by 1.12% to $1.9 billion in 2023, then increased by 25.84% to $2.4 billion in 2024, then rose by 22.89% to $2.9 billion in 2025.
  • Its last three reported values are $2.9 billion in Q3 2025, $2.9 billion for Q2 2025, and $2.5 billion during Q1 2025.